Samuels Louis, Emery Robert, Lattouf Omar, Grosso Michael, AlZeerah Masoud, Schuch Douglas, Wehberg Kurt, Muehrcke Derek, Dowling Robert
Lankenau Hospital, Wynnewood, Pennsylvania 19096, USA.
Heart Surg Forum. 2004;7(3):E218-29. doi: 10.1532/HSF98.20033011.
Coronary artery bypass and percutaneous intervention have become the established methods of coronary revascularization in treating angina pectoris. Subsets of angina patients, however, are not amenable to either of these procedures. Transmyocardial laser revascularization (TMR) has been developed as a potential treatment to address such patients, and clinical research to date illustrates the success of TMR for this patient group.
Although the symptoms of ischemic heart disease manifest themselves in a variety of ways, the best results with TMR are seen in patients with severe angina rather than in patients with silent ischemia or congestive heart failure. Potential TMR patients receive diagnostic tests to determine if and where the therapy should be applied. A recent cardiac catheterization is required to document the status of and the coronary-system suitability for the planned intervention. It is not appropriate to assume that a patient with nonbypassable, noninterventional coronary artery disease has to be relegated to medical therapy only. Additionally, echocardiography demonstrates the status of cardiac valves and segmental wall motion activity. This knowledge allows the surgeon to determine the sequence of surgery and if abnormalities are present. Once the decision to use TMR use has been made, there are 2 approaches--sole therapy or adjunctive therapy. TMR is not to be substituted for a feasible bypass graft, but the best time to make this decision may well be during the surgery itself, because grafts that appear surgically feasible on an angiogram may be less feasible after the chest has been opened. The decision to perform sole-therapy TMR in the absence of bypassable vessels clearly must be made before opening the chest. Whether to use cardiopulmonary bypass (CPB) and the sequence in which to perform TMR and bypass grafts are based on surgeon preference. The advantage of performing TMR on CPB is that channels can quickly be lased without pause. A potential advantage of performing TMR before bypass grafts is that "channel leak" (bleeding) can be minimized by the conclusion of the surgery. Complete revascularization has become technically more difficult because of the increasing use of percutaneous approaches and because patients are being referred for coronary artery bypass grafting much later in the course of their coronary disease progression than before. TMR may well be a viable alternative to bypassing a heavily diseased, previously intervened, small-diameter coronary artery. Thus, a model in which myocardial perfusion is considered within the context of the natural circulation can be conceived as an alternative to a model in which circulation is altered by interventional, surgical, and/or transmyocardial methods. TMR has been shown to be effective in accomplishing a complete revascularization when the restoration of circulation to ischemic territories with interventional therapy, bypass surgery, or a combination of both has been ineffective. We recommend that interested users follow this "complete revascularization strategy" algorithm for all ischemic vessels being considered for interventional or surgical treatment. Running each diseased vessel through this thought process will ensure that available treatment options are considered in the optimization of a patient's outcome.
The use of TMR for angina relief has evolved into a clinically proven technology that has enabled physicians to address difficult revascularization cases with a therapy that is safe and effective.
冠状动脉搭桥术和经皮介入治疗已成为治疗心绞痛时公认的冠状动脉血运重建方法。然而,有一部分心绞痛患者并不适合这两种治疗方法。心肌激光血运重建术(TMR)已被开发出来作为治疗这类患者的一种潜在方法,迄今为止的临床研究表明TMR对这一患者群体是成功的。
尽管缺血性心脏病的症状有多种表现形式,但TMR在严重心绞痛患者中取得的效果最佳,而非无症状性缺血或充血性心力衰竭患者。潜在的TMR患者需接受诊断测试,以确定是否以及在何处应用该治疗方法。近期需要进行心脏导管插入术,以记录计划干预的冠状动脉系统状况及适用性。不能认为患有不可搭桥、不可介入治疗的冠状动脉疾病的患者只能接受药物治疗。此外,超声心动图可显示心脏瓣膜的状况及节段性室壁运动情况。这些信息可帮助外科医生确定手术顺序以及是否存在异常情况。一旦决定采用TMR治疗,有两种方法——单纯治疗或辅助治疗。TMR不能替代可行的搭桥手术,但做出这一决定的最佳时机很可能是在手术过程中,因为血管造影显示在手术上可行的移植物在打开胸腔后可能变得不太可行。在没有可搭桥血管的情况下决定进行单纯治疗性TMR显然必须在打开胸腔之前做出。是否使用体外循环(CPB)以及进行TMR和搭桥手术的顺序取决于外科医生的偏好。在CPB上进行TMR的优点是可以不间断地快速激光打孔。在进行搭桥手术之前进行TMR的一个潜在优点是,手术结束时可将“通道渗漏”(出血)降至最低。由于经皮治疗方法的使用增加,以及患者在冠心病病程中比以前更晚才被转诊进行冠状动脉搭桥手术,完全血运重建在技术上变得更加困难。TMR很可能是绕过严重病变、先前已接受介入治疗的小直径冠状动脉的可行替代方法。因此,可以设想一种在自然循环背景下考虑心肌灌注的模式,作为一种替代通过介入、手术和/或心肌内方法改变循环的模式。当通过介入治疗、搭桥手术或两者结合恢复缺血区域的循环无效时,TMR已被证明在实现完全血运重建方面是有效的。我们建议有兴趣的使用者针对所有考虑进行介入或手术治疗的缺血血管遵循这种“完全血运重建策略”算法。对每一条病变血管都进行这样的思考过程将确保在优化患者治疗结果时考虑到所有可用的治疗选择。
使用TMR缓解心绞痛已发展成为一种临床验证的技术,使医生能够用一种安全有效的治疗方法来处理困难的血运重建病例。